2024年12月25日 · ERBB4 (Erb-B2 Receptor Tyrosine Kinase 4) is a Protein Coding gene. Diseases associated with ERBB4 include Amyotrophic Lateral Sclerosis 19 and Frontotemporal Dementia And/Or Amyotrophic Lateral Sclerosis 7. Among its related pathways are GPCR Pathway and Signaling by ERBB2 KD Mutants.

ERBB4 is a single-pass type I transmembrane protein with multiple furin-like cysteine rich domains, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif.

HER4, also known as ErbB4, is a member of epidermal growth factor receptor (EGFR) or ErbB family. HER4 is necessary for normal development of body systems including heart, nervous system, and mammary gland [ 1 ].

Here, we discuss the role of ErbB4 in normal physiology and in breast, lung, colorectal, gastric, pancreatic, prostate, bladder, and brain cancers, as well as in hepatocellular carcinoma, cholangiocarcinoma, and melanoma.

We review the mechanisms of ERBB4 signaling with an emphasis on mechanisms of signaling specificity. In the context of this signaling specificity, we discuss the hypothesis that ERBB4 appears to function as a tumor suppressor protein and as an oncoprotein.

ErbB4 is a 180-kDa transmembrane RTK that regulates cell proliferation and differentiation. The ErbB4 gene has been isolated as the fourth member of the human EGFR subfamily of tyrosine kinases. Four structurally different ErbB4 isoforms have been identified.

This new study by Kurokawa and colleagues highlights the role ErbB4 signaling as a critical backup system in ErbB2+ breast cancers. This study implied that Pan-ERBB inhibitors have efficacy in treating resistant tumors.

2024年2月16日 · Known effects were confirmed, and previously uncharacterized properties were discovered, such as pyrotinib’s preference for ERBB4 over EGFR. Additionally, two lead compounds selectively targeting ERBB4 were profiled, showing promise for clinical trials.

ErbB4/KITENIN-Mediated Signaling is Activated in Cetuximab-Resistant Colorectal Cancer Cells. Her4 promotes cancer metabolic reprogramming via the c-Myc-dependent signaling axis. ErbB4 regulate extracellular dopamine through the p38 MAPK signaling pathway.

We review the mechanisms of ERBB4 signaling with an emphasis on mechanisms of signaling specificity. In the context of this signaling specificity, we discuss the hypothesis that ERBB4 appears to function as a tumor suppressor protein and as an oncoprotein.